These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 15136407)
41. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia. Restrepo MI; Frei CR Am J Med; 2010 Apr; 123(4 Suppl):S39-46. PubMed ID: 20350634 [TBL] [Abstract][Full Text] [Related]
42. Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS "curb" index to assess severity. Loh LC Med J Malaysia; 2006 Mar; 61(1):128-30. PubMed ID: 16708753 [No Abstract] [Full Text] [Related]
45. [Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association]. Strålin K; Goscinski G; Hedlund J; Lidman C; Spindler C; Ortqvist A; Holmberg H Lakartidningen; 2008 Sep 17-23; 105(38):2582-7. PubMed ID: 18846863 [No Abstract] [Full Text] [Related]
46. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward? Ruhe J; Mildvan D Infect Dis Clin North Am; 2013 Mar; 27(1):115-32. PubMed ID: 23398869 [TBL] [Abstract][Full Text] [Related]
47. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342 [TBL] [Abstract][Full Text] [Related]
48. Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010-2018. Kimura T; Ito M; Onozawa S J Infect Chemother; 2020 Jul; 26(7):706-714. PubMed ID: 32284180 [TBL] [Abstract][Full Text] [Related]
49. Empiric oral monotherapy for hospitalized patients with community-acquired pneumonia: an idea whose time has come. Cunha BA Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):78-81. PubMed ID: 14727150 [No Abstract] [Full Text] [Related]
50. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Metlay JP; Waterer GW; Long AC; Anzueto A; Brozek J; Crothers K; Cooley LA; Dean NC; Fine MJ; Flanders SA; Griffin MR; Metersky ML; Musher DM; Restrepo MI; Whitney CG Am J Respir Crit Care Med; 2019 Oct; 200(7):e45-e67. PubMed ID: 31573350 [No Abstract] [Full Text] [Related]
51. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787 [TBL] [Abstract][Full Text] [Related]
52. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341 [TBL] [Abstract][Full Text] [Related]
53. The wobbly status of ketolides: where do we stand? Georgopapadakou NH Expert Opin Investig Drugs; 2014 Oct; 23(10):1313-9. PubMed ID: 25154307 [TBL] [Abstract][Full Text] [Related]
54. Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis. Kurotschka PK; Bentivegna M; Hulme C; Ebell MH J Gen Intern Med; 2024 May; 39(7):1214-1226. PubMed ID: 38360961 [TBL] [Abstract][Full Text] [Related]
55. Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia. Campbell GD Chest; 1999 Mar; 115(3 Suppl):14S-18S. PubMed ID: 10084454 [TBL] [Abstract][Full Text] [Related]